Beruflich Dokumente
Kultur Dokumente
Comit ejecutivo: Laura Fleider, Alejandra Maciel, Fernando Monge, Juan Carlos Sta-
ringer, Mariano Toziano, Andrea Velazco
Comit revisor: Myriam Perrotta, Juana lida Mauro, Baltasar Lema
ZT 1 y 2 ZT 3 ZT 1, 2 y 3
negativa o imagen grado 1 imagen grado 2 negativa imagen grado 2 negativa positiva
OPCIONAL: triage con test de HPV en citologa ASC-US en mayores de 24 aos (B I).
32 COLPOSCOPIA
En el caso de citologas con cambios mni- fismo y/o presencia de procesos inflamatorios,
mos (ASC-US y L-SIL), ante colposcopa ne- que en ocasiones es necesario corregir previo a
gativa, tener en cuenta la disminucin del tro- la reevaluacin.
Colposcopa (A II)
negativa positiva
Citologa - / Colpo +
Tamizaje solo con test de HPV c. Test de HPV negativo y citologa positi-
Se efecta a partir de los 30 aos. va: revisar la citologa.
a. Si el test es negativo, se repite cada 3 aos. - Cambios menores: repetir en un ao.
b. Si el test es positivo, se realiza posterior- - Cambios mayores: realizar colposcopa y
mente citologa y eventualmente colpos- evaluar conducto.
copa. d. Ambos estudios positivos: colposcopa.
Manejo de mujeres con diagnstico histolgico de L-SIL (CVP y CIN 1) con correlacin
cito-colpo-histolgica
1) Seguimientos intratamiento por 2 aos
2) Tratamiento en paciente de alto riesgo: segn criterio y evaluacin del mdico tratante.
negativa positiva*
Menor de 25 aos: > 25 a. o ZT
control citocolposcpico tipo 3: tto. escisional
c/6 meses por 2 aos
en ZT tipos 1 y 2
conposibilidad de
seguimiento o tto. escisional
* Hay poca evidencia hastael momento del manejo conservadordel CIN 2 con p16 positiva.
H-SIL:
Control citocolposcpico cada 12 semanas y eventual biopsia ante sospecha de progresin
(A I).
Reevaluacin en el posparto.
BIBLIOGRAFIA
1. Moyer VA; U.S. Preventive Services Task For- Conference. 2006 American Societyfor Colposcopy and Cer-
ce. Screening for cervica l cancer: U.S. Preventive Services vical Pathology-sponsored Consensus Conference. Am J Obs-
Task Force recommendation statement. Ann Intern Med. tet Gynecol. 2007;197:340-5.
2012;156:880-91. 7. J. Jordan, P. Martin-Hirsch, M. Arbyn, U. Schenck, J.-
2. Committee on Practice Bulletins-Gynecology. ACOG J. Baldauf, D. Da Silva**, A. Anttila, P. Nieminen and W.
Practice Bulletin Number 131: Screening for cervical cancer. Prendiville. European guidelines for clinical management of
Obstet Gynecol. 2012;120:1222-38. abnormal cervical cytology, Part 2. Cytopathology 2009, 20,
3. Saslow D, Solomon D, Lawson HW, Killackey M, 516.
Kulasingam SL, Cain J, et al; ACS-ASCCP-ASCP Cervical 8. Edward E. Partridge, MD; Nadeem R. Abu-Rustum,
Cancer Guideline Committee. American Cancer Society, MD; Susan M. Campos, MD, MPH, MS; Patrick J. Fahey, MD;
American Society for Colposcopy and Cervical Pathology, and Michael Farmer, MD; Rochelle L. Garcia, MD; Anna Giuliano,
American Society for Clinical Pathology screening guidelines PhD; Howard W. Jones III, MD; Subodh M. Lele, MD; Richard
for the prevention and early detection of cervical cancer. CA W. Lieberman, MD; Stewart L. Massad, MD; Mark A. Morgan,
Cancer J Clin. 2012;62:147-72. MD; R. Kevin Reynolds, MD; Helen E. Rhodes, MD; Diljeet K.
4. George F. Sawaya, MD; ShaliniKulasingam, PhD; Tho- Singh, MD, DrPH; Karen Smith-McCune, MD, PhD; Nelson
mas D. Denberg, MD, PhD; and Amir Qaseem, MD, PhD, Teng, MD, PhD; Cornelia LiuTrimble, MD; Fidel Valea, MD;
MHA. Cervical cancer screening in average-risk women: and Sharon Wilczynski, MD, PhD. Cervical cancer screening.
best practice advice from the clinical guidelines committee Clinical practice guidelines in oncology. JNCCNJournal
of the American College of Physicians. Ann Intern Med. of the National Comprehensive Cancer Network,Volume 8,
2015;162:851-859. Number 12, December 2010.
5. L. Stewart Massad, MD, Mark H. Einstein, MD, War- 9. Prevencin del cncer de crvico-uterino. Recomenda-
ner K. Huh, MD, Hormuzd A. Katki, PhD, Walter K. Kin- ciones para el tamizaje seguimiento y tratamiendo de mujeres
ney, MD, Mark Schiffman, MD, Diane Solomon, MD, Ni- para la prevencin del cancercrvico-uterino en el marco de
colasWentzensen, MD, and Herschel W. Lawson, MD. 2012 la incorporacon de la prueba de VPH. Ministerio de Salud y
Updated consensus guidelines for the management of abnor- Accin Social. Instituto Nacional del Cncer.
mal cervical cancer screening tests and cancer precursors. 2012 10. Kimberly K. Vesco, MD, MPH; Evelyn P. Whitlock,
ASCCP Consensus Guidelines Conference American Society MD, MPH; Michelle Eder, PhD; Brittany U. Burda, MPH;
for Colposcopy and Cervical Pathology. Journal of Lower Ge- Caitlyn A. Senger, MPH; and Kevin Lutz, MFA. Risk fac-
nital Tract Disease, Volume 17, Number 5, 2013, S1YS27. tors and other epidemiologic considerations for cervical
6. Thomas C. Wright Jr, MD; L. Stewart Massad, MD; cancer screening: a narrative review for the U.S. Preventi-
Charles J. Dunton, MD; Mark Spitzer, MD; Edward J. Wil- ve Services Task Force. http://www.annals.org/content/ea
kinson, MD; Diane Solomon, MD. 2006 Consensus guidelines rly/2011/10/14/0003-4819-155-10-201111150-00377.full
for the management of women with cervical intraepithelial 10/19/2011.
neoplasia or adenocarcinoma in situ. 2006 American Society 11. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS,
for Colposcopy and Cervical Pathology-sponsored Consensus Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM,
Volumen 26 - N 1 - Ao 2015 37
Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC; Members of bie Saslow, PhD,10 Mark Schiffman, MD, MPH,11 Nicolas
the LAST Project Work Groups. The lower anogenital squa- Wentzensen, MD, PhD,11 Herschel W. Lawson, MD,12 and
mous terminology standardization project for HPV-associated Mark H. Einstein, MS13. Use of Primary High-Risk Human
lesions: background and consensus recommendations from the Papillomavirus Testing for Cervical Cancer Screening: Interim
College of American Pathologists and the American Society Clinical Guidance. J Lower Gen Tract Dis 2015;19: 9196.
for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. *Representatives from the Society of Gynecologic Oncology,
2013 Jan;32(1):76-115. American Society for Colposcopy and Cervical Pathology,
12. Manejo de las citologas anormales. Manejo de la neo- American College of Obstetricians and Gynecologists, Ameri-
plasia Intraepitelial cervical y del adenocarcinoma in situ. can Cancer Society, American Society of Cytopathology, Co-
Guas de Manejo 2009. S.A.P.T.G.I.yC. y S.O.G.I.B.A. llege of American Pathologists, and the American Society for
13. Revista Colposcopa. rgano de difusin de la Socie- Clinical Pathology, convened to provide interim guidance for
dad Argentina de Patologa del Tracto Genital Inferior y Col- primary hrHPV screening.
poscopa. Volumen 21 N 1 . Ao 2010. Pag. 40-48. http://col- 15. L. Stewart Massad, MD, Mark H. Einstein, MD, War-
poweb.org/docs/consenso_definitivo_ginecologia_4-10-14.pdf ner K. Huh, MD,Hormuzd A. Katki, PhD, Walter K. Kinney,
14. Warner K. Huh, MD,1 Kevin A. Ault, MD,2 David MD, Mark Schiffman, MD, Diane Solomon, MD, Nicolas
Chelmow, MD,3 Diane D. Davey, MD,4 Robert A. Goulart, Wentzensen, MD, and Herschel W. Lawson, MD. 2012 Upda-
MD,5 Francisco A. Garcia, MD, MPH,6 Walter K. Kinney, tes Consensus Guidelines for the Management of Abnormal
MD,7L. Stewart Massad, MD,8 Edward J. Mayeaux, MD,9 Deb- Cervical Cancer Screening Tests and Cancer Precursors